satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroids
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Neuromyelitis Optica Spectrum Disorder
Conditions
Neuromyelitis Optica Spectrum Disorder
Trial Timeline
Mar 2, 2021 → May 28, 2024
NCT ID
NCT04660539About satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroids
satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroids is a phase 3 stage product being developed by Roche for Neuromyelitis Optica Spectrum Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT04660539. Target conditions include Neuromyelitis Optica Spectrum Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04660539 | Phase 3 | Completed |
Competing Products
8 competing products in Neuromyelitis Optica Spectrum Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Satralizumab 120 mg | Chugai Pharmaceutical | Approved | 85 |
| Satralizumab + Placebo + Baseline Treatment | Chugai Pharmaceutical | Phase 3 | 77 |
| Satralizumab + Placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| Satralizumab | Roche | Phase 3 | 77 |
| UPLIZNA | Amgen | Pre-clinical | 22 |
| Inebilizumab | Amgen | Phase 2 | 51 |
| Inebilizumab | Amgen | Approved | 84 |
| intravenous methylprednisolone | Brain Biotech | Pre-clinical | 15 |